ENTX
Entera Bio Ltd. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$3.20Close
$147.8MMarket cap
$1.00 – $3.9252-week range
Nov 13, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 96 · stronger than 96% of stocks over 12 months
Cautions
- Results soon Nov 13, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
18%
1wk
up 9.6%
price change
1mo
up 10.0%
price change
12-month return
up 13%
market up 11% ·
its own up 6%
F-score
2 / 9
Weak
Altman Z
18.29
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
11.3×
price / book
Earnings yield
down 8.2%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
down 77%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 108%
return on equity
Free cash margin
down 17802%
-$7.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profits backed by cash
- reduced long-term debt
Trade setup
ATR%
6.8%
$0.22 a day · 2×ATR $2.77
RS
96 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
1.11
50 sessions
Implied move
—
no option chain · report Nov 13, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 18.9% over the year, from 39m to 46m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 5.0% to 0.0%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 76.8% over the year, from $181,000 to $42,000.
Last reported
Aug 7, 2026
Results reaction
Aug 7, 2026+7% vs market2 sessions after results
Financials
- Gross 0%
- Net -27236%
- Free cash -17802%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $365,000 | $571,000 | $134,000 | $0 | $181,000 | $42,000 |
| Gross margin | 18% | 35% | 25% | — | 5% | 0% |
| Operating income | -$11.2M | -$12.2M | -$13.0M | -$8.9M | -$9.6M | -$11.5M |
| Net income | -$11.2M | -$12.2M | -$13.1M | -$8.9M | -$9.5M | -$11.4M |
| Net margin | -3073% | -2134% | -9754% | — | -5271% | -27236% |
| Earnings per share | — | -$0.47 | -$0.45 | -$0.31 | -$0.25 | -$0.25 |
| Free cash flow | -$10.6M | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.5M |
| Free cash margin | -2907% | -1590% | -9363% | — | -3769% | -17802% |
| Cash | $8.6M | $24.9M | $12.3M | $11.0M | $8.7M | $7.1M |
| Shareholders' equity | $7.5M | $22.6M | $11.8M | $10.4M | $8.1M | $13.1M |
| Shares outstanding | 21.06m | 28.80m | 28.81m | 35.48m | 38.84m | 46.18m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 7, 2026 | Quarterly ↗ | Jun 30, 2026 | 38d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Mar 27, 2026 | Annual ↗ | Dec 31, 2025 | 86d |
| Nov 14, 2025 | Quarterly ↗ | Sep 30, 2025 | 45d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Mar 28, 2025 | Annual ↗ | Dec 31, 2024 | 87d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Mar 8, 2024 | Annual ↗ | Dec 31, 2023 | 68d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 6, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 18, 2026 | Regulation FD · Other events ↗ |
| Aug 7, 2026 | Results · Regulation FD ↗ |
| Jul 28, 2026 | Material agreement · Unregistered share sale · Director or officer change ↗ |
| Jul 16, 2026 | Director or officer change · Charter or bylaws · Shareholder vote ↗ |
| May 8, 2026 | Results · Regulation FD ↗ |
| Apr 3, 2026 | Material agreement · Unregistered share sale ↗ |
| Mar 27, 2026 | Results · Regulation FD ↗ |
| Mar 4, 2026 | Regulation FD ↗ |
| Feb 9, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 4, 2026 | Material agreement · Director or officer change · Regulation FD ↗ |
| Nov 14, 2025 | Results · Regulation FD ↗ |